KEY TAKEAWAYS
- The study aimed to investigate the efficacy and safety of chemo with RT in treating patients with LACC.
- The primary endpoints were to determine OS and PFS.
- Researchers observed nab-paclitaxel plus cisplatin yields superior outcomes in LACC treatment; further investigation is ongoing.
Ida Hude Dragičević and the team aimed to assess the efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in treating locally advanced cervical cancer (LACC).
They performed an inclusive analysis of retrospective data collected from patients with LACC treated at their institution. Patients were categorized into three groups: the single-agent cisplatin (DDP) chemoradiotherapy group, the paclitaxel plus cisplatin (TP) chemoradiotherapy group, and the nanoparticle albumin-bound (nab-) paclitaxel combined with cisplatin (nPP) chemoradiotherapy group.
The primary endpoints focused on overall survival (OS) and progression-free survival (PFS), while secondary endpoints included objective response rate (ORR) and the incidence of adverse events (AEs).
About 124 patients were enrolled, with 32 in the DDP group, 41 in the TP group, and 51 in the nPP group. Significant differences were observed in OS (P = 0.041, HR 0.527, 95% CI 0.314-0.884) and PFS (P = 0.003, HR 0.517, 95% CI 0.343-0.779) among the 3 groups. The 2-year OS rate was notably higher in the nPP group compared to the DDP group (92.2% vs. 85.4%, P = 0.012).
Similarly, the 2-year PFS rates were significantly increased in the TP group (78.0% vs. 59.4%, P = 0.048) and the nPP group (88.2% vs. 59.4%, P = 0.001) compared to the DPP group. The nPP group exhibited a significantly superior 2-year PFS rate compared to the DDP group (88.2% vs. 59.4%, P = 0.001). Additionally, the ORR was significantly higher in the nPP group compared to the DDP group (P = 0.013), while no statistically significant differences were found in the incidence of AE’s among the groups (P > 0.05).
The study concluded that in the treatment of LACC, cisplatin-based doublet chemotherapy regimens, particularly nab-paclitaxel plus cisplatin, demonstrate superior efficacy compared to paclitaxel plus cisplatin, with manageable AE’s. These findings offer valuable insights into the clinical management of LACC; however, further prospective studies are warranted to validate these results.
The study received no funds.
Source: https://pubmed.ncbi.nlm.nih.gov/38745137/
Wu Y, Jiang P, Chen Z, et al. (2024). “Efficacy and safety of different chemotherapy regimens concurrent with radiotherapy in the treatment of locally advanced cervical cancer.” BMC Cancer. 2024 May 15;24(1):589. doi: 10.1186/s12885-024-12358-8. PMID: 38745137; PMCID: PMC11094845.
